Study on effective prevention of chemotherapy-induced nausea and vomiting based on genetic polymorphism

Not Applicable

• Conditions: Breast Cancer

• Registration Number: JPRN-UMIN000007135
• Lead Sponsor: nivercity of Shizuoka

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-01-25
• Study Completion: 2014-12-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 180

Inclusion Criteria

Not provided

Exclusion Criteria

1) Known prior severe hypersensitivity to anthracyclines, cyclophosphamide, 5HT3 receptor antagonist, corticosteroids and NK-1 receptor antagonists 2) Patients who do not have enough whole body state to the antineoplastic agents treatment 3) Pregnant, breastfeeding or expecting woman 4) Patient with severe uncontrollable diabetes mellitus 5) Known symptomatic brain metastasis 6) Other clinical difficulties in this study

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Proportion of complete response (defined as no emesis and no rescue treatment). [Time Frame: overall; 0-120hr(during and post chemotherapy), acute phase;0-24hr, delayed phase 24-120hr]